Molecular Imaging of Vulnerable Coronary Plaque with Radiolabeled Somatostatin Receptors (SSTR)

Journal of Clinical Medicine

Jose Nelson Rivera¹  Luz Kelly Anzola²  Fernando Mut³  Alberto Signore⁴  Juan Carlos Ramirez⁵ 

[1] Internal Medicine Department, Clinica Reina Sofia, Bogota 110121, Colombia;Nuclear Medicine Department, Clinica Reina Sofia, Bogota 110121, Colombia;Nuclear Medicine Department, Hospital Italiano, Montevideo 11600, Uruguay;Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, Italy;Postgraduate Program in Nuclear Medicine Fundacion, Universitaria Sanitas, Bogota 111021, Colombia;

关键词: atherosclerosis;    vascular inflammation;    PET/CT;    ⁶⁸Ga-DOTA-TATE;    activated macrophages;   

DOI  :  10.3390/jcm10235515

来源: DOAJ

【 摘 要 】

Atherosclerosis is responsible for the majority of heart attacks and is characterized by several modifications of the arterial wall including an inflammatory reaction. The silent course of atherosclerosis has made it necessary to develop predictors of disease complications before symptomatic lesions occur. Vulnerable to rupture atherosclerotic plaques are the target for molecular imaging. To this aim, different radiopharmaceuticals for PET/CT have emerged for the identification of high-risk plaques, with high specificity for the identification of the cellular components and pathophysiological status of plaques. By targeting specific receptors on activated macrophages in high-risk plaques, radiolabelled somatostatin analogues such as ⁶⁸Ga-DOTA-TOC, TATE,0 or NOC have shown high relevance to detect vulnerable, atherosclerotic plaques. This PET radiopharmaceutical has been tested in several pre-clinical and clinical studies, as reviewed here, showing an important correlation with other risk factors.

【 授权许可】

Unknown